Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 4/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6484844 | 0.86 | DYRK1A (0.36) | ALDH1A1KDM4EMAPTHSD17B10LMNA | |
| SCHEMBL6101410 | 0.86 | CLK4 (0.35) | ALDH1A1HSD17B10LMNAALOX15CYP1A2 | |
| SCHEMBL6102963 | 0.83 | LMNA (0.32) | LMNAL3MBTL1 | |
| SCHEMBL6102611 | 0.83 | LMNA (0.33) | HSD17B10LMNAL3MBTL1CCNA2CDK2 | |
| SCHEMBL6100024 | 0.82 | AXL (0.31) | ALDH1A1KDM4EMAPTLMNAL3MBTL1 | |
| SCHEMBL6102252 | 0.82 | BRD4 (0.37) | ALDH1A1KDM4EMAPTHSD17B10LMNA | |
| SCHEMBL6102606 | 0.82 | SLC2A1 (0.32) | LMNAL3MBTL1CCNA2CDK2CDK5 | |
| SCHEMBL6101403 | 0.81 | TRPA1 (0.39) | ALDH1A1KDM4EMAPTHSD17B10LMNA | |
| SCHEMBL6101749 | 0.81 | DYRK1A (0.46) | ALDH1A1KDM4EHSD17B10HPGDKDR | |
| SCHEMBL6100595 | 0.80 | TLR7 (0.37) | CCNA2CDK2CDK5DYRK1ACDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-13 | — | — | US | disclosed |
| EP-2575455-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | The Regents of the University of California (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011153377-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | WO | disclosed |
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | NEUROGEN CORPORATION | 2006-01-19 | — | — | US | disclosed |
| US-6936617-B2 | Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands | NEUROGEN CORPORATION (US) | 2005-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | GABRA5, GABRA2, GABBR1 | ALDH1A1 797/4885KDM4E 2625/4885MAPT 2174/4885 |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | ALDH1A1 1701/4885KDM4E 3317/4885MAPT 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.